3 blood tests for tumor cells in metastatic breast or prostate cancer
Compares 3 blood tests in metastatic breast or prostate cancer.
Plain-language title generated from the registry record
Registry title: Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
Key facts
- Where
- Toulouse, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic breast cancer or metastatic prostate cancer who have not yet started a new cancer treatment. A blood sample is taken once to compare three tests that find cancer cells in the blood.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Breast cancer (any subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, with many metastases (multi-metastatic), ready for a new line of treatment. WHO performance status 2 or lower.
- Earlier treatment
- Must not yet have started a new specific treatment for breast or prostate cancer.
Main reasons for not taking part
- Other illnesses that could disrupt the study procedure
- Personal, family, geographic or social situation that prevents following the study
- Deprived of liberty or under legal protection (guardianship)
- Another solid tumour in the last 5 years (breast or cervix carcinoma in situ is allowed)
- Not covered by the French Social Security scheme
Read by machine on 12 November 2026.
Where in France
- IUCT-OToulouse, FranceContact: Florence DALENCTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institut Claudius Regaud
- Trial code
- NCT06904625
- Record updated
- 27 May 2026
- Original description
This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques.Read full original descriptionShow less
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques.
Each patient will participate in the study for one day.
A total of 54 evaluable patients (36 patients with metastatic breast cancer and 18 patients with metastatic prostate cancer) will be included in this interventional study.
Inclusion: Patient with breast cancer (whatever the immunohistochemical subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, multi-metastatic, eligible for a new line of treatment; Patient not yet initiated on a new specific treatment for breast or prostate cancer at inclusion; Age ≥ 18 years and WHO ≤ 2; Patient affiliated to Social Security scheme in France; Patient having signed informed consent prior to inclusion in the study and prior to any study-specific procedures.
Exclusion: Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures stipulated in the study protocol; Associated pathology(ies) likely to prevent the study procedure from running smoothly; Patient deprived of liberty or under legal protection (guardianship, legal protection); Patient who has had another solid tumor (excluding carcinoma in situ of the breast or cervix) within 5 years.